Investors showed appetite for Metsera’s IPO, as shares of the clinical-stage metabolic medicines biotech popped 47% in their Nasdaq debut. Maze Therapeutics and Beta Bionics also priced IPOs ...

Investing.com -- Metsera, a clinical-stage biotechnology firm, debuted on the Nasdaq Global Select Market today. After initially offering its common stock to the public at $18.00 per share, the ...

At $289m, Metsera’s IPO would be on the higher end of listings since the start of 2024. “This significant raise could serve as a catalyst for other similar companies considering entering the ...

While Metsera is offering less shares, 15.3 million, than the 17.2 million it had planned in recent days, the final IPO price of $18 per share has exceeded the $15-$17 range it had initially expected.

Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and related conditions. Read our initial report here on Seeking Alpha.

Metsera, Inc. prices its IPO at $18 per share, raising approximately $275 million to fund obesity treatments. Quiver AI Summary. Metsera, Inc., a clinical-stage biotechnology company specializing ...

Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable appetite for such ...

Metsera plans to use the IPO to fund a phase 3 trial of MET-097i—a subcutaneous GLP-1 receptor agonist that is the company’s most advanced asset—through top-line results, ...

Metsera's IPO is richest among the Friday debutantes . New York-based Metsera priced 15.28 million shares at $18 apiece to raise $275 million as the largest of the IPOs pricing for Friday ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read why MTSR stock is a Strong Buy.

Metsera reports $156.26 million loss in first nine months of 2024 Proceeds from IPO to fund MET-097i clinical trials Weight-loss drug market projected to reach $150 billion by early 2030s Jan 10 ...

IPO Report Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon ... At the closing bell, Metsera’s stock MTSR stood at $26.50, well above its IPO pricing level of $18.